Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients
| Autor: | Jun Li, Xinyue Chen, Yong Chen, Chong-Wen Si, Zheng Zeng, Zhong-hou Han, Hadad Ivan, Yanyan Yu, Dong-Ming Hou, Hai-ying Lu, Li-wei Zhuang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
HBEAG POSITIVE
Adult Male Hepatitis B virus Genotype Virus Replication Antiviral Agents Hepatitis B Chronic Chronic hepatitis Predictive Value of Tests mental disorders Medicine Humans Hepatitis B e Antigens business.industry Gastroenterology virus diseases Interferon-alpha General Medicine Middle Aged Virology Treatment efficacy digestive system diseases Treatment Outcome Liver Lamivudine Immunology DNA Viral Drug Therapy Combination Female business Rapid Communication |
| Popis: | To evaluate the effect of antiviral agents on intrahepatic HBV DNA in HBeAg-positive chronic hepatitis B patients.Seventy-one patients received treatment with lamivudine, interferon alpha (IFN-alpha 2b) or sequential therapy with lamivudine-IFN-alpha 2b for 48 wk. All subjects were followed up for 24 wk. Serum and intrahepatic HBV DNA were measured quantitatively by PCR. HBV genotypes were analyzed by PCR-RFLP.At the end of treatment, the intrahepatic HBV DNA level in 71 patients decreased from a mean of (6.1 +/- 1.0) log10 to (4.9 +/- 1.4) log10. Further, a larger decrease was seen in the intrahepatic HBV DNA level in patients with HBeAg seroconversion. Intrahepatic HBV DNA level (before and after treatment) was not significantly affected by the patients' HBV genotype, or by the probability of virological flare after treatment.Intrahepatic HBV DNA can be effectively lowered by antiviral agents and is a significant marker for monitoring antivirus treatment. Low intrahepatic HBV DNA level may achieve better efficacy of antivirus treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|